ASH 2021 | Targeting TCF3-HLF−positive ALL
Sarah Tasian
• 13 Dec 2021
TCF3-HLF-positive B-acute lymphoblastic leukemia (B-ALL) is a rare subtype of B-ALL with no known effective treatments. Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, describes the development of novel therapies to treat TCF3-HLF-positive B-ALL. Aurora kinase A (AURKA) and RasGAP were both identified as potential targets that can overcome resistance to current chemotherapy and transplant regimens. Addition of venetoclax, a BCL-2 inhibitor, with a small molecule inhibitor targeting AURKA or RasGAP may successfully treat this rare subtype with synthetic lethality. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
